WIBG, ZNF706 and GABARAPL2 | ||||||||
---|---|---|---|---|---|---|---|---|
Anti-CCP | RF | PAD4 | WIBG | ZNF706 | GABARAPL2 | combination | ||
RA <1 year (n = 124) vs 186 controls (AS, PsA, SLE, SSc, and healthy) | Sensitivity (%) | 70 | 68 | 18.5 | 33 | 18.5 | 23 | 48 |
Specificity (%) | 98 | nd | 91 | 98 | 98 | 96 | 94 | |
PPV (%) | 96 | nd | 57 | 93 | 85 | 80 | 84 | |
NPV (%) | 81 | nd | 63 | 69 | 64 | 65 | 73 | |
RA <1 year negative for anti-CCP (n = 37) vs 186 controls (AS, PsA, SLE, SSc, and healthy) | Sensitivity (%) | 0 | 24 | 11 | 16 | 11 | 27 | 43 |
Specificity (%) | nd | nd | 91 | 98 | 98 | 96 | 94 | |
PPV (%) | nd | nd | 19 | 67 | 50 | 59 | 59 | |
NPV (%) | nd | nd | 84 | 86 | 85 | 87 | 89 | |
RA <1 year negative for RF (n = 39) vs 186 controls (AS, PsA, SLE, SSc, and healthy) | Sensitivity (%) | 23 | 0 | 10 | 15 | 15 | 28 | 44 |
Specificity (%) | 98 | nd | 91 | 98 | 98 | 96 | 94 | |
PPV (%) | 69 | nd | 19 | 67 | 60 | 61 | 61 | |
NPV (%) | 84 | nd | 83 | 85 | 85 | 86 | 89 | |
RA <1 year negative for anti-CCP and RF (n = 28) vs 186 controls (AS, PsA, SLE, SSc, and healthy) | Sensitivity (%) | 0 | 0 | 4 | 7 | 11 | 32 | 39 |
Specificity (%) | nd | nd | 91 | 98 | 98 | 96 | 94 | |
PPV (%) | nd | nd | 5 | 40 | 43 | 56 | 50 | |
NPV (%) | nd | nd | 86 | 87 | 88 | 90 | 91 |